Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fecal Microbiota(University Hospital Heidelberg) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Fecal Microbiota(University Hospital Heidelberg): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market
9 min read
ORJ-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ORJ-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
IBR-822 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
IBR-822: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Sanqi Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Sanqi Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
C-PTBE-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
C-PTBE-01: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HP-5120 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
HP-5120: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AD-101(01 Life) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
AD-101(01 Life): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SHD-999 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
SHD-999: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AMG-436 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
AMG-436: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
TYRA-200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
TYRA-200: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SLX-200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
SLX-200: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ITM-XX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ITM-XX: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.